SCHEMBL9102212

SCHEMBL9102212

CC(=O)Cc1cccc(F)c1C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
RIPK1 Q13546 3/20 0.39
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
MAOB P27338 1/20 0.38
CXCL8 P10145 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
HDAC4 P56524 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
IAPP P10997 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868842 0.85 CXCL8 (0.53) P2RX7SMN1; SMN2CXCL8
SCHEMBL30858615 0.83 P2RX7 (0.47) P2RX7SMN1; SMN2CES2CES1RIPK1
SCHEMBL11205828 0.82 RIPK1 (0.46) P2RX7L3MBTL1CES2CES1RIPK1
SCHEMBL125583 0.82 ALDH1A1 (0.49) L3MBTL1RIPK1MAOBCXCL8NPC1
SCHEMBL28357376 0.81 ANO1 (0.47) P2RX7L3MBTL1CES2CES1MAOB
SCHEMBL9101675 0.80 P2RX7 (0.42) P2RX7SMN1; SMN2CES2CES1RIPK1
SCHEMBL16112668 0.80 P2RX7 (0.45) P2RX7SMN1; SMN2L3MBTL1RIPK1CXCL8
SCHEMBL9103347 0.80 P2RX7 (0.42) P2RX7SMN1; SMN2CES2CES1RIPK1
SCHEMBL7188564 0.80 L3MBTL1 (0.43) P2RX7SMN1; SMN2L3MBTL1ESR1ESR2
SCHEMBL24173599 0.79 ANO1 (0.43) SMN1; SMN2L3MBTL1CES2CES1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459557-B1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-09-18 EP disclosed
US-8415336-B2 Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals SANOFI (FR) 2013-04-09 US disclosed
US-20120232081-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-13 US disclosed
EP-2459557-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232081-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, ACE, PM20D2 P2RX7 761/4885SMN1; SMN2 4824/4885L3MBTL1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.